Pharmaceutical compositions and methods for effecting dopamine release

US6525065B1 · kind B1 · utility

Assignee

• Targacept, Inc. · US

Inventors

• William Scott Caldwell · Winston-Salem, US
• Merouane Bencherif · Winston-Salem, US
• Gary Maurice Dull · Lewisville, US
• Peter A. Crooks · Lexington, US
• Patrick M. Lippiello · Clemmons, US

Key dates

• Filing date: Jun 30, 1997
• Grant date: Feb 25, 2003
• Expiry date: Jun 30, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D453/02
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.